You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Amoxicillin; clarithromycin; lansoprazole - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for amoxicillin; clarithromycin; lansoprazole and what is the scope of patent protection?

Amoxicillin; clarithromycin; lansoprazole is the generic ingredient in two branded drugs marketed by Ani Pharms, Rising, Sandoz, and Takeda Pharms Usa, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for amoxicillin; clarithromycin; lansoprazole

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	1
Clinical Trials:	22
DailyMed Link:	amoxicillin; clarithromycin; lansoprazole at DailyMed

Recent Clinical Trials for amoxicillin; clarithromycin; lansoprazole

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fu Jen Catholic University Hospital	Phase 4
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile	N/A
Miguel O'Ryan Gallardo	N/A

See all amoxicillin; clarithromycin; lansoprazole clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for amoxicillin; clarithromycin; lansoprazole

US Patents and Regulatory Information for amoxicillin; clarithromycin; lansoprazole

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PREVPAC (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	050757-001	Dec 2, 1997		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Ani Pharms	LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	200218-001	Aug 30, 2013		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Sandoz	LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	202588-001	Mar 4, 2014	AB	RX	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Rising	LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	206006-001	Oct 7, 2016	AB	RX	No	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for amoxicillin; clarithromycin; lansoprazole

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	PREVPAC (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	050757-001	Dec 2, 1997	⤷ Subscribe	⤷ Subscribe
Takeda Pharms Usa	PREVPAC (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	050757-001	Dec 2, 1997	⤷ Subscribe	⤷ Subscribe
Takeda Pharms Usa	PREVPAC (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	050757-001	Dec 2, 1997	⤷ Subscribe	⤷ Subscribe
Takeda Pharms Usa	PREVPAC (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	050757-001	Dec 2, 1997	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Amoxicillin; clarithromycin; lansoprazole Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Amoxicillin, Clarithromycin, and Lansoprazole

Introduction to the Drugs

Amoxicillin

Amoxicillin is a widely used antibiotic belonging to the penicillin group, effective against various bacterial infections.

Clarithromycin

Clarithromycin is a macrolide antibiotic used to treat a variety of bacterial infections, though it is not as prominently discussed in recent market reports as amoxicillin and lansoprazole.

Lansoprazole

Lansoprazole is a proton pump inhibitor (PPI) used to treat conditions such as duodenal and stomach ulcers, NSAID-induced gastric ulcers, erosive esophagitis, and gastroesophageal reflux disease (GERD).

Market Dynamics for Amoxicillin

Market Size and Growth

The global amoxicillin market has been growing steadily. In 2023, the market size was valued at $4.58 billion and is expected to reach $4.74 billion in 2024, with a compound annual growth rate (CAGR) of 3.4%[1][4].

Forecasted Growth

By 2028, the market is projected to grow to $5.44 billion at a CAGR of 3.5%. From 2023 to 2030, the market is expected to maintain a CAGR of 4.5%, driven by factors such as the increasing prevalence of infectious diseases and rising healthcare expenditure[1][4].

Drivers of Growth

Increased Healthcare Expenditure: Higher healthcare spending ensures wider accessibility and availability of amoxicillin, leading to higher prescription rates and improved patient outcomes[1].
Research and Development: Innovations such as reformulated versions of antibiotics and new classes of medications are enhancing treatment outcomes and driving market growth[1].

Challenges

Antibiotic Resistance: The emergence of antibiotic-resistant bacterial strains poses a significant challenge to the market[4].
Regulatory Hurdles: Strict regulations surrounding antibiotic use can hinder market growth[4].

Market Dynamics for Lansoprazole

Market Size and Growth

The global lansoprazole market was valued at $1.89 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030, reaching nearly $2.81 billion by 2030[5].

Regional Insights

The North American region is expected to dominate the lansoprazole market due to a high prevalence of GERD in the United States and a larger demand for sustained release proton pump inhibitor medicines[5].

Drivers of Growth

Increasing Prevalence of GERD: The high frequency of GERD in regions like North America drives the demand for lansoprazole[5].
Product Types: The availability of various product types such as capsules, OD tablets, and intravenous formulations contributes to market growth[5].

Key Players

Major players in the lansoprazole market include Takeda Pharmaceutical, Teva Pharmaceuticals, Sandoz, GSK, Dr. Reddy's, and others[2].

Market Dynamics for Clarithromycin

While specific recent market reports on clarithromycin are limited, it is part of the broader macrolide antibiotic market. Here are some general insights:

Market Position

Clarithromycin, though not as prominently discussed, is part of the antibiotic market that faces similar challenges and opportunities as amoxicillin. The market for macrolide antibiotics is influenced by factors such as antibiotic resistance and regulatory environments.

Challenges

Antibiotic Resistance: Similar to amoxicillin, clarithromycin faces the challenge of antibiotic-resistant bacterial strains[4].
Generic Competition: Many antibiotics, including macrolides, are available in generic forms, which can affect the revenue of brand-name drugs[3].

Financial Trajectory

Amoxicillin

Current Market Size: $4.58 billion in 2023[1].
Projected Growth: Expected to reach $5.44 billion by 2028 and maintain a CAGR of 4.5% from 2023 to 2030[1][4].

Lansoprazole

Current Market Size: $1.89 billion in 2023[5].
Projected Growth: Expected to reach $2.81 billion by 2030 with a CAGR of 5.8%[5].

Clarithromycin

While specific financial projections are not available, the overall antibiotic market trends suggest that clarithromycin would follow similar growth patterns influenced by the prevalence of infections and antibiotic resistance.

Key Takeaways

Amoxicillin: The market is driven by increased healthcare expenditure, research and development, and the growing prevalence of infectious diseases, but faces challenges such as antibiotic resistance.
Lansoprazole: The market is driven by the increasing prevalence of GERD, especially in North America, and the availability of various product types.
Clarithromycin: Part of the broader macrolide antibiotic market, it faces challenges like antibiotic resistance and generic competition.

FAQs

What is the projected market size for amoxicillin by 2028?

The amoxicillin market is expected to grow to $5.44 billion by 2028 at a CAGR of 3.5%[1].

What drives the growth of the lansoprazole market?

The growth of the lansoprazole market is driven by the increasing prevalence of GERD, especially in North America, and the availability of various product types[5].

What are the main challenges facing the amoxicillin market?

The main challenges include the emergence of antibiotic-resistant bacterial strains and regulatory hurdles surrounding antibiotic use[4].

Which region is expected to dominate the lansoprazole market?

The North American region is expected to dominate the lansoprazole market due to a high prevalence of GERD in the United States[5].

How does healthcare expenditure impact the amoxicillin market?

Increased healthcare expenditure ensures wider accessibility and availability of amoxicillin, leading to higher prescription rates and improved patient outcomes[1].

Sources

GlobeNewswire: "Amoxicillin Market Research Report 2024: Combination Therapies and Immunotherapy Trends Shaping Future Landscape - Global Long-term Forecast to 2028 and 2033"[1].
Valuates Reports: "Lansoprazole - Market Size"[2].
Harvard Kennedy School: "Sizing A Market Entry Reward for the Development of New Antibiotics"[3].
MarkWide Research: "Amoxicillin Market to Witness Steady Growth with a Projected CAGR of 4.5% over 2023-2030"[4].
Maximize Market Research: "Lansoprazole Market: Global Industry Analysis and Forecast"[5].

More… ↓

⤷ Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.